|
Fume Hood
 Thermo Fisher Scientific Inc., a leader in serving science, has introduced new lines to its Thermo Scientific Hamilton Infinity and Advantage Fume Hoods.
...continue
Flow Cytometer
BD Biosciences, a segment of BD, announced the launch of the BD FACSAria III Cell Sorting System, a next-generation flow cytometer with the ability to run complex multicolor experiments using up to six lasers.
...continue
TIRF Objective
 Olympus, a leader in objective-based total internal reflection fluorescence (TIRF) microscopy, continues to support scientists with three new high-performance TIRF objectives.
...continue
Precast Gels
Bio-Rad Laboratories, Inc. has launched Mini-PROTEAN TGX (Tris-Glycine eXtended) precast gels, providing researchers with the fastest running, long shelf life precast gels on the market for protein electrophoresis using the standard Laemmli buffer system.
...continue
Knockout Rat Models
Sigma Life Science extended its portfolio of knockout rat models with the announcement of a new suite of models designed to facilitate more predictive absorption, distribution, metabolism, excretion and toxicity (ADME/Tox) studies.
...continue
|
|
More New Technologies
|
|
|
Target: Teamwork
 Successful marriages between drug developers and technology providers are changing the landscape of GPCR-targeted pharmaceuticals. Such partnerships offer a range of benefits to all parties involved, including expertise, services, and exchange of technology.
...continue
|
|
|
 Genomics & Proteomics
|
Policy & Projections
Conflicts of Interest
 The National Institutes of Health (NIH) has been stung in recent years by numerous reports of financial conflicts of interest involving staff scientists and drug, biotech, and medical device companies.
...continue
|
Technology Advances
Cool Chromatography
 When analyzing a sample with chromatography, accuracy and efficiency depends on sample handling. With mass spectrometry (MS), for example, the technology should maximize the sample ions that get directed into the instrument.
...continue
|
|
|
Divestiture of MDS Pharma Services Completed
MDS Inc., announced the completion of the divestiture of the remaining MDS Pharma Services (Discovery through Phase IIa) operations to Ricerca Biosciences LLC.
...continue
Ricerca to Acquire Early-Stage Portion of MDS Pharma
Ricerca Biosciences, LLC, announced its execution of a purchase agreement to acquire the Discovery and Preclinical business of MDS Pharma Services with facilities in Bothell, Washington; Lyon, France; and Taipei, Taiwan.
...continue
PPD Opens Research Facility in Ireland
PPD, Inc. has officially opened its contract research facility in Athlone, Ireland, which includes an 18,000-square-foot analytical testing laboratory and clinical supplies business.
...continue
|
|
More CRO News
|
|
The rapidly growing knowledge base in drug discovery and protein research has placed increased pressure on researchers to quickly gain a greater understanding of protein-protein interactions, cell signaling pathways, and markers of metabolic processes.
Multiplex bead assays allow simultaneous analysis of multiple targets within one reaction, providing more information and higher sensitivity while using less sample than traditional ELISA assays.
Translational pharmaceutics enable the rapid development, manufacture, and clinical evaluation of new oral formulations.
Pharmaceutical companies continue to use an array of data management systems to keep pace and keep track of their preclinical study data.
Copley Scientific will introduce the DUSA shaker, which automates the rinsing of DUSA collection tubes, enhancing the reproducibility of drug recovery, especially for low solubility formulations.
Mettler Toledo launched the LiquiPhysics Excellence instruments for density and refractive index determinations within the pharma industry.
Researchers from Solvay Pharmaceuticals Inc. have used the Morphologi G3 image analysis based particle characterization system from Malvern Instruments to examine an API manufactured at two different facilities to determine if they can be seen as equivalent.
BLP25 Liposome Vaccine is an investigational therapeutic cancer vaccine currently being evaluated for the treatment of unresectable, stage III non-small cell lung cancer (NSCLC) and inoperable, locally advanced, recurrent, or metastatic breast cancer.
Cilengitide is the first in a new class of investigational targeted anti-cancer therapies—called integrin inhibitors—to reach Phase 3 development.
As is common in all drug discovery and development projects, upon the identification of promising lead compounds, the next steps usually involve initial safety tests in animal subjects.
